The next time you hear someone call for a supercycle, Cramer wants you to run — not walk — straight for the exit. A little over a year ago, Cramer warned that sand plays were in danger. He wasn't just worried that the price of crude had collapsed; he was worried that the word "supercycle" would take this group down the tubes.
Commodity sand stocks refer to companies that provide sand for hydraulic fracturing, the drilling method that has been essential to unlock oil and gas reserves in the U.S. Cramer's fear was that sand stocks such as Emerge Energy Services, U.S. Silica and Hi-Crush Partners had skyrocketed immensely, and would not be able to withstand the cut in oil prices that has plagued black crude in the past year.
What really alarmed Cramer was when an analyst from Morgan Stanley came out and called for a fracking sand supercycle. His opinion was that there was a prolonged period of production growth and stronger pricing for sand plays as part of a secular shift in the oil industry.
"The next time you hear some expert call for a commodity supercycle, remember the annihilation of these fracking sand stocks, and do some selling," Cramer said. (Tweet this)
Read MoreCramer: When you hear this word—run far away!
Another biotech stock that has been subject to heat over the recent political firestorm issue of drug pricing, is TG Therapeutics, part of the development stage biotechs that have been hit the hardest.
The reason why this group has been hit the hardest, is because their valuation is entirely dependent on how much money they can potentially make from drugs that could be released years in the future. Thus, with investor worries that Congress might impose price controls, there are worries about the future.
TG Therapeutics is a developer of monoclonal antibody based treatment for various types of cancer. Its pipeline includes two blood cancer drugs that could have fantastic results for patients. The company recently received FDA approval to run a phase 3 trial on both of these drugs together as a treatment for chronic lymphocytic leukemia.
So, while its stock has been hammered, the company has some positive developments happening. To learn more, Cramer spoke with the company's chairman and CEO, Mike Weiss.
"The key to the company, our belief, is that getting drugs to market is one thing, but pricing is going to be an issue…And again, obviously we are not running a charity, we are here to sell drugs and sell it at a reasonable price, and I think we can get there without price gouging. I know there are a lot of issues about that right now," Weiss said.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
United Continental Holdings: "I like Oscar Munoz [CEO]...I think it's good. I think that group has bottomed here and liked it. I know some analysts want to say negative things. Not me!"
Twitter: "I wanted Jack Dorsey [new CEO] I think Dorsey is going to do a good job. I was kind of hoping he would resign from Square and let someone else handle that. But the changes are coming fast and furious at Twitter and he is liked by the staff and he cares about those who Tweet."
Read MoreLightning Round: What Dorsey will do for Twitter